TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24206541
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial non‐pharmacologic interventions including better compliance with prescribed medication, regular blood pressure measurements, healthy diet, regular physical activity, and cognitive training.
Study: 21510308
Drug: 5000 IE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IE Heparin (0.2 ml of 25000 IE)
Study: 21510308
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml 0.9% NaCL (placebo)
Study: 18608554
Drug: Tangerine tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangerine tomato sauce (300 g per day)
Study: 18608554
Drug: Red tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red tomato sauce (300 g per day)
Study: 15330955
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg kg(‐1) intramuscular midazolam by Bioject injector
Study: 15330955
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg kg(‐1) subcutaneous midazolam by J‐Tip injector
Study: 15330955
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg kg(‐1) oral midazolam
Study: 11519531
Drug: Hyoscine N-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butylbromide (10 mg p.o. t.i.d. for 24 h)
Study: 11367646
Drug: Salvia Miltiorrhizae
Normalized name: Salvia miltiorrhiza root extract
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia Miltiorrhizae Composita (SMC) 200 mg/kg administered intravenously before operation and during rewarming period
Study: 11367646
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (control group)
Study: 7921099
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including home visits weekly during the first year and biweekly thereafter, and attendance at a child development center 5 days a week from 12 months to 3 years
Study: 28640529
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors (CsA)
Study: 25856035
Drug: 30‐second injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐second injection duration
Study: 25856035
Drug: 30‐second injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐second injection duration and 5‐minute dry cold application
Study: 25856035
Drug: 10-second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-second injection duration with no dry cold application
Study: 22145255
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (2 mL)
Study: 22145255
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline (2 mL)
Study: 19095357
Drug: 5% hypertonic
Normalized name: Walgreens Sodium Chloride 5% Hypertonicity Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% hypertonic saline injection (0.25ml) into the infra-patellar fat pad
Study: 10702449
Drug: 0.125% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% ropivacaine with fentanyl 2 microg/mL
Study: 9061108
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine intra-articularly + saline intramuscularly
Study: 9061108
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pethidine intra-articularly + saline intramuscularly
Study: 9061108
Drug: Saline intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intramuscularly + 1 mg morphine intra-articularly
Study: 9061108
Drug: Saline intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intramuscularly + 10 mg pethidine intra-articularly
Study: 3594019
Drug: Hearing aid
Normalized name: hearing aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearing aid use for more than 2 hours daily
Study: 3594019
Drug: Hearing aid
Normalized name: hearing aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearing aid use for less than 2 hours daily
Study: 31177305
Drug: Photodynamic diagnosis
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic diagnosis and 6 weekly optimized mitomycin C instillations
Study: 28506548
Drug: Antiarrhythmic medication
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic medication (AAD)
Study: 26667497
Drug: Intranasal sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sterile saline (Control)
Study: 19875752
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment strategies
Study: 14572568
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of absolute ethanol (group I, n = 42)
Study: 14572568
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both methods (group III, n = 42)
Study: 1357894
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg b.i.d. for 10 days
Study: 1357894
Drug: Phenoxymethyl-penicillin 1
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl-penicillin 1 g b.i.d. for 10 days
Study: 29643231
Drug: OCDC (oxidized
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCDC (oxidized autologous whole‐tumor cell lysate) administered alone (cohort 1, n = 5)
Study: 29643231
Drug: OCDC in
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCDC in combination with bevacizumab (cohort 2, n = 10)
Study: 29643231
Drug: OCDC in
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCDC in combination with bevacizumab plus low‐dose intravenous cyclophosphamide (cohort 3, n = 10)
Study: 27858069
Drug: Anti-gingivitis IgY
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-gingivitis IgY toothpaste used twice daily for 3 minutes
Study: 24941838
Drug: Ligustrazine Hydrochloride
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine Hydrochloride (LH) 3 mg/kg intravenously infused and added in CPB priming
Study: 17917696
Drug: Creatine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g x d(‐1))
Study: 17917696
Drug: Carbohydrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (20 g x d(‐1))
Study: 16025961
Drug: Quyu Xiaoban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quyu Xiaoban capsule (QXC)
Study: 10399048
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for injection
Study: 26865133
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% 20 ml
Study: 26865133
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% 5 ml
Study: 26388539
Drug: Integrated Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Cognitive Behavioral Therapy (ICBT) plus Standard Care (SC)
Study: 26388539
Drug: Medication Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Assisted Treatment (MAT)
Study: 23824248
Drug: 5‐HT2A receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT2A receptor blockade with ketanserin
Study: 18848957
Drug: Cocaine alone
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine alone (0.2 mg/kg, IV)
Study: 18848957
Drug: Cocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.2 mg/kg, IV) + Nalbuphine (5 mg/70 kg, IV)
Study: 10992868
Drug: Modified drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified drug delivery system (study group)
Study: 10992868
Drug: Existing drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing drug delivery system (control group)
Study: 7662481
Drug: Lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (20 ml of 1% lidocaine)
Study: 7662481
Drug: Pethidine/diazepam (intravenous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine/diazepam (intravenous)
Study: 2526706
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg flunarizine for 3 months
Study: 26121746
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg daily taken orally for 1 week)
Study: 24171699
Drug: Neck-specific exercise
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck-specific exercise followed by prescription of physical activity
Study: 24171699
Drug: Neck-specific exercise
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck-specific exercise with a behavioural approach followed by prescription of physical activity
Study: 24171699
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of physical activity alone without neck-specific exercises
Study: 18498882
Drug: Ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablets
Study: 18498882
Drug: Ibuprofen liquigels
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen liquigels
Study: 8777252
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including cisplatin; specific dosage and duration not mentioned.
Study: 8777252
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment alone; specific details not mentioned.
Study: 24170099
Drug: 12 or
Normalized name: Ry-T-12 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 or 24 mg iv alemtuzumab
Study: 24170099
Drug: 44 μg
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 μg sc interferon‐β‐1a (SC IFNB‐1a, Rebif)
Study: 20652232
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha administration
Study: 12145002
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g EPA/d (n = 12)
Study: 12145002
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g DHA/d (n = 12)
Study: 2300545
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (6 g prior to phenylpropanolamine and 3 g every 4 hr for 16 hr)
Study: 29981573
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (proparacaine eye drop)
Study: 25028379
Drug: Rilonacept 160
Normalized name: RILONACEPT 160 mg in 2 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Arcalyst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept 160 mg
Study: 2497720
Drug: Fish-oil concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil concentrate (4.0 g omega-3 fatty acids)
Study: 2497720
Drug: Fish-oil concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil concentrate (7.5 g omega-3 fatty acids)
Study: 2497720
Drug: Fish-oil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil treatment (both doses)
Study: 2497720
Drug: Fish-oil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil treatment (F4 dose)
Study: 2497720
Drug: Fish-oil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil treatment (F7.5 dose)
Study: 336174
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of 6-mercaptopurine (6-MP)
Study: 29055953
Drug: Caffeine-based topical
Normalized name: caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine-based topical liquid 0.2%
Study: 16776693
Drug: BoNTA (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNTA (various doses)
Study: 8878241
Drug: Amoxicillin/clavulanate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (40 mg/kg/day in three divided doses for 10 days)
Study: 6301110
Drug: Radio-/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio-/chemotherapy
Study: 6301110
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy or combined palliative chemotherapy
Study: 31950924
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin/10 mg solifenacin
Study: 31950924
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration for six weeks
Study: 30328058
Drug: Quercetin Phytosome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin Phytosome (new formulation based on food-grade lecithin)
Study: 30278517
Drug: Nicotine Patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine Patch (NP)
Study: 30278517
Drug: Smoking Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking Deprivation combined with Placebo Patch (SD+PP)
Study: 30278517
Drug: Smoking Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking Deprivation combined with Nicotine Patch (SD+NP)
Study: 26709597
Drug: 0.5% benvitimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% benvitimod cream
Study: 26709597
Drug: 1.0% benvitimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% benvitimod cream
Study: 26709597
Drug: 1.5% benvitimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% benvitimod cream
Study: 26709597
Drug: 0% (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% (placebo) benvitimod cream
Study: 17724151
Drug: Cold‐adapted influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold‐adapted influenza vaccine, trivalent (CAIV‐T)
Study: 17724151
Drug: Frozen live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen live attenuated influenza vaccine (LAIV)
Study: 12469002
Drug: Quetiapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (up to 75 mg/day)
Study: 9855508
Drug: Pergolide (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.05 to 0.65 mg/day)
Study: 19697647
Drug: Resilient appliance
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resilient appliance therapy (T group)
Study: 8318446
Drug: Sequential constraint
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential constraint during treatment
Study: 8318446
Drug: Quantitative restriction
Normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative restriction during treatment
Study: 29973195
Drug: J. regia
Approvals — FDA: no, EMA: no, PMDA: no
Description: J. regia leaf extract (100 mg, twice daily for 8 weeks)
Study: 29973195
Drug: Placebo (microcrystalline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (microcrystalline cellulose, twice daily for 8 weeks)
Study: 28247624
Drug: Pathogenetic spermatoprotective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogenetic spermatoprotective therapy including zinc and selenium based dietary supplement and chorionic gonadotropin
Study: 28247624
Drug: Etiotropic TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiotropic TB therapy (control group)
Study: 26002052
Drug: Riluzole (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (maximum dose 200 mg/day)
Study: 26002052
Drug: D-serine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (maximum dose 30 mg/kg/day)
Study: 22955689
Drug: YKL-40 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: YKL-40 levels in patients with MACE (194±104 μg/L)
Study: 19919581
Drug: Lidocaine 2
Normalized name: lidocaine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2 mg/kg i.v., followed by 2 mg/kg/h i.v.
Study: 19919581
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg/kg i.v., followed by 25 mg/kg/h i.v.
Study: 15994216
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment with interferon alpha-2b and ribavirin
Study: 1676776
Drug: Air breathing
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air breathing followed by inhalation of allergen diluent (placebo)
Study: 1676776
Drug: Ozone followed
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone followed by inhalation of allergen diluent
Study: 6634352
Drug: Olfactory aversion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olfactory aversion therapy
Study: 27192132
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 6.8 g/kg‐1 of slushie with application of iced towels to the legs, torso and back/arms (ST)
Study: 27192132
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 6.8 g/kg‐1 of room temperature (22.3°C) sports drink (CON)
Study: 22688312
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose followed by 75 mg maintenance dose
Study: 22688312
Drug: Ticlopidine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 100 mg twice daily
Study: 12684609
Drug: Amisulpride (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400-800 mg/day)
Study: 8831181
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20 mg b.i.d.
Study: 8831181
Drug: Metoprolol (OROS)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (OROS) 14/190 mg o.d.
Study: 8831181
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metoprolol and nifedipine
Study: 1336463
Drug: lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (20 mg/40 mg o.d.)
Study: 1336463
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg/100 mg o.d.)
Study: 4016825
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg bolus, intravenous)
Study: 31060838
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral nutrition (14.1 g/100 mL carbohydrate)
Study: 31060838
Drug: Intervention enteral
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention enteral nutrition (7.4 g/100 mL carbohydrate)
Study: 29047161
Drug: Prophylactic donor
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic donor lymphocyte infusion (DLI)
Study: 24582316
Drug: GSK679586 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK679586 (10 mg/kg, once-monthly intravenous infusions)
Study: 22158915
Drug: Pseudoephedrine (PSE)
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine (PSE) 2.5 mg/kg
Study: 19880909
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol 420 mg bid for 2 weeks
Study: 8374246
Drug: Intravenous zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous zinc supplementation for 2 months
Study: 3946944
Drug: Ophthalmic timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic timolol (0.5%)
Study: 18501861
Drug: Prenatal drug
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal drug exposure (PDE) group
Study: 18501861
Drug: Non-drug-exposed children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug-exposed children (control group)
Study: 15804071
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg/day for 12 weeks
Study: 15804071
Drug: Placebo tablet/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet/day for 12 weeks
Study: 27138022
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of VGX-1027 (1-800 mg)
Study: 27138022
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of VGX-1027 (40-400 mg)
Study: 27138022
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of VGX-1027
Study: 27138022
Drug: Drug accumulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug accumulation
Study: 27138022
Drug: Excretion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excretion of VGX-1027
Study: 12019482
Drug: Auricularum powder
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U)
Study: 12019482
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Auricularum powder, Ciprofloxacin, Tobramycin)
Study: 9786607
Drug: Cilnidipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (5 to 20 mg once daily)
Study: 9786607
Drug: Nisoldipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (5 to 20 mg once daily)
Study: 7941918
Drug: Diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 300 mg od
Study: 7941918
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg bd
Study: 7941918
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg od